Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (NQ: KNSA )

22.50 +0.95 (+4.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 611,587
Open 21.65
Bid (Size) 21.50 (2)
Ask (Size) 23.90 (10)
Prev. Close 21.55
Today's Range 21.59 - 22.63
52wk Range 16.56 - 28.15
Shares Outstanding 71,726,685
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst
Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis. 
Via Benzinga
Earnings Scheduled For February 25, 2025
Via Benzinga

Performance

YTD
+12.84%
+12.84%
1 Month
+14.80%
+14.80%
3 Month
+5.88%
+5.88%
6 Month
-7.56%
-7.56%
1 Year
+10.08%
+10.08%

More News

Read More
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Exploring Kiniksa Pharmaceuticals's Earnings Expectations
Via Benzinga
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
From Kiniksa Pharmaceuticals, Ltd.
Via GlobeNewswire
Earnings Outlook For Kiniksa Pharmaceuticals
Via Benzinga
Earnings Outlook For Kiniksa Pharmaceuticals
Via Benzinga
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
KNSA Stock Earnings: Kiniksa Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via AB Newswire
Topics ETFs
Exposures Product Safety
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via TheNewswire.com
Topics ETFs
Exposures Product Safety
KNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in December
Via InvestorPlace
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
Via InvestorPlace
Topics Economy
Exposures Economy
Earnings Scheduled For April 23, 2024
Via Benzinga
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
Via Investor's Business Daily
5 Value Stocks In The Healthcare Sector
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+
Via Investor's Business Daily
ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold
Via Investor's Business Daily
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
Exelixis Stock Sees Rising Relative Strength Rating
Via Investor's Business Daily
Dynavax Technologies Stock Sees Renewed Technical Strength
Via Investor's Business Daily
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.